We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to VAL-083

Expanded access is currently available for this treatment.
Verified May 2017 by DelMar Pharmaceuticals, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03138629
First Posted: May 3, 2017
Last Update Posted: May 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
DelMar Pharmaceuticals, Inc.
  Purpose
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Condition Intervention
Cancer Drug: VAL-083

Study Type: Expanded Access     What is Expanded Access?
Available for Individual Patients
Available for Intermediate-size Population
Official Title: Expanded Access to VAL-083

Further study details as provided by DelMar Pharmaceuticals, Inc.:

Intervention Details:
    Drug: VAL-083
    VAL-083 will be administered intravenously
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patient has relapsed/refractory disease and exhausted all standard treatments.

Exclusion Criteria:

  • Patient is eligible for a VAL-083 clinical trial.
  • Patient has previously received VAL-083 for the same disease.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03138629


Contacts
Contact: Lorena Lopez, B.S. (925) 292-8360 llopez@solsentinel.com
Contact: John Langlands, Ph.D. (604) 629-5989 jlanglands@delmarpharma.com

Sponsors and Collaborators
DelMar Pharmaceuticals, Inc.
  More Information

Responsible Party: DelMar Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03138629     History of Changes
Other Study ID Numbers: DLM-17-002
First Submitted: May 1, 2017
First Posted: May 3, 2017
Last Update Posted: May 3, 2017
Last Verified: May 2017